The real time Cbot A singleplex assays developed by the Flurosentric Inc. is the only assays that can be used with exsiting, valadated and platforms for detection of botulinum toxin genes.

The Government intends to solicit, negotiate and award to only one contractor using other than full and open competition procedures pursuant to the authority of FAR 13.106-1(b)(1). The NAICS code for this acquisition is 325413 and the small business size standard is 500 employees. This requirement will be procured under the guidelines of FAR Part 12, Commercial Items. Award will be made using Simplified Acquisition Procedures, FAR Part 13.

The Cbot A Singleplex Assay (50,000 Rxn) PCR assays are required for support of federal, state, and local public health laboratories to detect Clostridium botulinum using exsiting protocols and platforms. In order to ensure that the assays perform as required , the assays must contain the identical oligonucleotide sequence and have the same specificity and sensitivity as that developed by Fluresentric.

Fluoresentric Inc. must also provide technical support.

Interested parties should submit a capabilities statement demonstrating their ability to provide the required system to Deborah T. Workman by email at [email protected]. This notice of intent is not a request for competitive proposals; however, the Government shall consider all responses received. A determination by the CDC not to compete this proposed contract, based upon responses to this notification, is solely within the discretion of the Contracting Officer.